

# Lawrence B Afrin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8880581/publications.pdf>

Version: 2024-02-01

59  
papers

1,435  
citations

430442

18  
h-index

344852

36  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1400  
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. <i>International Journal of Infectious Diseases</i> , 2020, 100, 327-332.	1.5	219
2	Mast Cell-Mediated Mechanisms of Nociception. <i>International Journal of Molecular Sciences</i> , 2015, 16, 29069-29092.	1.8	117
3	Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. <i>Journal of Hematology and Oncology</i> , 2011, 4, 10.	6.9	107
4	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	6.3	95
5	Mast cell activation symptoms are prevalent in Long-COVID. <i>International Journal of Infectious Diseases</i> , 2021, 112, 217-226.	1.5	85
6	Mast cell disorders in Ehlers-Danlos syndrome. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2017, 175, 226-236.	0.7	76
7	Characterization of Mast Cell Activation Syndrome. <i>American Journal of the Medical Sciences</i> , 2017, 353, 207-215.	0.4	65
8	Diagnosis of mast cell activation syndrome: a global consensus. <i>Diagnosis</i> , 2021, 8, 137-152.	1.2	59
9	Pharmacological treatment options for mast cell activation disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 671-694.	1.4	53
10	Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. <i>Annals of Medicine</i> , 2016, 48, 190-201.	1.5	51
11	Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 314-321.	2.0	36
12	Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. <i>F1000Research</i> , 2017, 6, 1889.	0.8	35
13	A concise, practical guide to diagnostic assessment for mast cell activation disease. <i>World Journal of Hematology</i> , 2014, 3, 1.	0.1	33
14	Mast Cell Activation Syndrome: A Primer for the Gastroenterologist. <i>Digestive Diseases and Sciences</i> , 2021, 66, 965-982.	1.1	32
15	Mast cell activation disease and the modern epidemic of chronic inflammatory disease. <i>Translational Research</i> , 2016, 174, 33-59.	2.2	28
16	Fatal Copper Deficiency From Excessive Use of Zinc-Based Denture Adhesive. <i>American Journal of the Medical Sciences</i> , 2010, 340, 164-168.	0.4	26
17	Leveraging of open EMR architecture for clinical trial accrual. <i>AMIA ... Annual Symposium proceedings</i> , 2003, , 16-20.	0.2	23
18	Mast Cell Activation Disease and Microbiotic Interactions. <i>Clinical Therapeutics</i> , 2015, 37, 941-953.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Polycythemia From Mast Cell Activation Syndrome: Lessons Learned. American Journal of the Medical Sciences, 2011, 342, 44-49.	0.4	17
20	Mast cell activation may explain many cases of chemical intolerance. Environmental Sciences Europe, 2021, 33, .	2.6	16
21	Successful treatment of mast cell activation syndrome with sunitinib. European Journal of Haematology, 2015, 95, 595-597.	1.1	14
22	Sclerosing mediastinitis and mast cell activation syndrome. Pathology Research and Practice, 2012, 208, 181-185.	1.0	13
23	Utility of hydroxyurea in mast cell activation syndrome. Experimental Hematology and Oncology, 2013, 2, 28.	2.0	13
24	Mast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease. American Journal of the Medical Sciences, 2014, 348, 460-464.	0.4	13
25	Improving clinical trial accrual by streamlining the referral process. International Journal of Medical Informatics, 2015, 84, 15-23.	1.6	13
26	Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome. American Journal of the Medical Sciences, 2019, 357, 507-511.	0.4	13
27	Burning mouth syndrome and mast cell activation disorder. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 111, 465-472.	1.6	12
28	Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding. Journal of Obstetrics and Gynaecology, 2019, 39, 664-669.	0.4	12
29	Restless legs syndrome is associated with mast cell activation syndrome. Journal of Clinical Sleep Medicine, 2020, 16, 401-408.	1.4	12
30	Restless legs syndrome is associated with long-COVID in women. Journal of Clinical Sleep Medicine, 2022, 18, 1413-1418.	1.4	12
31	Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis. International Journal of Molecular Sciences, 2021, 22, 8960.	1.8	11
32	Mast Cell Activation Syndrome Masquerading as Agranulocytosis. Military Medicine, 2012, 177, 113-117.	0.4	10
33	Successful targeted treatment of mast cell activation syndrome with tofacitinib. European Journal of Haematology, 2017, 99, 190-193.	1.1	10
34	Mast cell activation disorder masquerading as pure red cell aplasia. International Journal of Hematology, 2010, 91, 907-908.	0.7	9
35	Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50â€“100 Å— 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts. Blood, 2012, 120, 176-176.	0.6	7
36	Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50â€“100x10<sup>9</sup>/L. Journal of Clinical Oncology, 2012, 30, 6630-6630.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Mast cell activation syndrome in pregnancy, delivery, postpartum and lactation: a narrative review. <i>Journal of Obstetrics and Gynaecology</i> , 2020, 40, 889-901.	0.4	6
38	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. <i>Clinical Transplantation</i> , 2011, 25, E271-E275.	0.8	5
39	Some cases of hypermobile <sc>Ehlersâ€“Danlos</sc> syndrome may be rooted in mast cell activation syndrome. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2021, 187, 466-472.	0.7	5
40	Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 â€“) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2022, 22, 336-346.	0.2	5
41	Mast cell deposition and activation may be a new explanation for epiploic appendagitis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224689.	0.2	4
42	Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome. <i>Blood</i> , 2015, 126, 5194-5194.	0.6	4
43	Case Report: Treatment of systemic mastocytosis with sunitinib. <i>F1000Research</i> , 2017, 6, 2182.	0.8	4
44	Web Access to the American Society of Hematology Slide Bank. <i>Blood</i> , 1999, 93, 2425-2426.	0.6	3
45	A new era for an old cell: heightened appreciation of mast cell disease emerges. <i>Translational Research</i> , 2016, 174, 1-4.	2.2	3
46	Characterization Of Common Blood Test Abnormalities Potentially Aiding Diagnosis Of Mast Cell Activation Syndrome: A Preliminary Analysis. <i>Blood</i> , 2013, 122, 5240-5240.	0.6	3
47	Mast Cell Regulatory Gene Variants Are Common in Mast Cell Activation Syndrome. <i>Blood</i> , 2016, 128, 4878-4878.	0.6	3
48	Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?. <i>Vaccines</i> , 2022, 10, 127.	2.1	3
49	Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome. <i>Oncology</i> , 2014, 28, 129-31, 134.	0.4	3
50	Response to: â€œIn reply to: â€“Mast Cell Disorders in Ehlersâ€“Danlos Syndromeâ€™ (Jaime Vengoechea,) Tj ETQq0 0 0 rgBT /Overlock 176, 251-252.	0.7	2
51	The Significance of Mast Cell Activation in the Era of Precision Medicine. <i>American Journal of Gastroenterology</i> , 2018, 113, 1725-1726.	0.2	2
52	1194â€“Small Intestinal Bacterial Overgrowth Is Common in Mast Cell Activation Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, S671-S671.	0.2	2
53	Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 3933-3933.	0.6	2
54	Utilities of Various Mast Cell Mediators in Diagnosing Mast Cell Activation Syndrome. <i>Blood</i> , 2015, 126, 5174-5174.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Web Access to the American Society of Hematology Slide Bank. Blood, 1999, 93, 2425-2426.	0.6	1
56	Characterization of Mast Cell Activation Syndrome. Blood, 2016, 128, 3683-3683.	0.6	1
57	Support group webcasting: a feasibility assessment. AMIA ... Annual Symposium proceedings, 2005, , 880.	0.2	0
58	General medicine in South Carolina, 1905-2005: the science and the art as recorded in The Journal of the South Carolina Medical Association. The Journal of the South Carolina Medical Association, 2005, 101, 129-36.	0.0	0
59	Evaluation of a tryptase depletion index for better pathologic identification of mast cell activation syndrome. Zeitschrift Fur Gastroenterologie, 2022, , .	0.2	0